⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.
Partial Reprogramming
Current understanding
Yamanaka-factor rejuvenation — the field’s biggest bet (Altos et al.) and biggest safety question.
Evidence log
- 2026-10-07 — KHL Foundation Reports the Likely First Human Partial Epigenetic Reprogramming Treatments: 2026 KHL Foundation news report describes entrepreneurial longevity-community individuals receiving AAV-delivered partial epigenetic reprogramming via medical-tourism providers — framed as likely first-in-human partial reprogramming, ahead of Life Biosciences’ formal optic-neuropathy trial; no peer-reviewed outcome data, no safety follow-up, trend/narrative signal only. [anecdotal-biohack] (novelty: 4)
- 2026-10-04 — Protracted Fate Acquisition and Epigenetic De‐Aging During Induced Neural Stem Cell Conversion of Human Blood Cells: Human blood-to-iNSC direct conversion using SOX2/cMYC (not full OSKM) shows a multi-week protracted fate acquisition during which epigenetic de-aging unfolds, with established iNSC lines retaining only ~5–13% of donor epigenetic age — extends reprogramming-linked rejuvenation to a non-iPSC lineage-conversion route in human cells, in vitro only. [mechanism-plausible] (novelty: 3)
- 2026-10-01 — Protracted Fate Acquisition and Epigenetic De-Aging During Induced Neural Stem Cell Conversion of Human Blood Cells.: In vitro human blood-to-iNSC conversion study using SOX2/cMYC (not full OSKM) shows epigenetic de-aging and NSC fate acquisition are protracted multi-week processes, with established iNSC lines retaining only ~5–13% of donor epigenetic age and losing age-associated cellular hallmarks — extends the ‘reprogramming erases epigenetic age’ claim to a direct (non-iPSC) lineage-conversion route in human cells, no in vivo or outcome data. [mechanism-plausible] (novelty: 3)
- 2026-10-01 — Traditional Chinese Medicine Formulas in Delaying Aging: From Theoretical Foundations to Molecular Mechanisms and Translational Perspectives.: 2026 TCM-and-aging review touches reprogramming/epigenetic rejuvenation only peripherally, framing proteomic aging clocks (not reprogramming per se) as the readout of choice for evaluating whether TCM formulas reset aging biology — conceptual, no reprogramming data. [expert-opinion] (novelty: 3)
- 2026-09-16 — Aging as Loss of Biological Self-Correction: A Geroscience Framework for Longevity, Inflammaging, and Restored Resilience.: 2026 self-correction framework review nominates partial reprogramming among interventions that could restore lost recovery capacity, while cautioning that recovery-trajectory metrics (not clock reversal alone) would be the appropriate readout; conceptual framing, no new reprogramming data. [expert-opinion] (novelty: 3)
- 2026-06-17 — Resetting the epigenetic clock: cellular senescence and regenerative strategies in intervertebral disc degeneration.: 2026 IDD review positions cellular reprogramming as the terminal ‘seed’ step of a clear–prime–seed regenerative sequence for disc cells, extending the reprogramming pitch to a load-bearing musculoskeletal tissue with no primary reprogramming data of its own. [expert-opinion] (novelty: 3)
- 2026-07-01 — The Molecular Basis of Ocular Aging: Mechanisms, Pathologies, and Emerging Therapeutics.: 2026 ocular-aging review nominates partial epigenetic reprogramming as an emerging therapeutic to reverse age-related epigenetic drift in ocular tissues (RPE, retinal neurons, trabecular meshwork), extending the reprogramming pitch beyond the widely cited OSK optic-nerve regeneration precedent — narrative synthesis, no new reprogramming data. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
KHL Foundation Reports the Likely First Human Partial Epigenetic Reprogramming Treatments
07-oct-2026
novelty 4
per-area 4
strengthens
Protracted Fate Acquisition and Epigenetic De‐Aging During Induced Neural Stem Cell Conversion of Human Blood Cells
04-oct-2026
novelty 3
per-area 3
strengthens
Protracted Fate Acquisition and Epigenetic De-Aging During Induced Neural Stem Cell Conversion of Human Blood Cells.
01-oct-2026
novelty 3
per-area 3
strengthens
Traditional Chinese Medicine Formulas in Delaying Aging: From Theoretical Foundations to Molecular Mechanisms and Translational Perspectives.
01-oct-2026
novelty 3
per-area 3
strengthens
Aging as Loss of Biological Self-Correction: A Geroscience Framework for Longevity, Inflammaging, and Restored Resilience.
16-sep-2026
novelty 3
per-area 3
strengthens
A Mechanism-Based Framework for Anti-Aging Strategies: From Metabolic Regulation to Senotherapy and Stem Cell-Based Interventions.
01-sep-2026
novelty 2
per-area 2
mentions
Decoding the multidimensional landscape of skin aging: molecular pathways and next-generation diagnostics & therapeutics.
25-aug-2026
novelty 2
per-area 2
mentions
Cellular Senescence and Aging: Mechanisms, Disease Convergence, and Therapeutic Frontiers.
05-jul-2026
novelty 2
per-area 2
mentions
The Molecular Basis of Ocular Aging: Mechanisms, Pathologies, and Emerging Therapeutics.
01-jul-2026
novelty 3
per-area 3
strengthens
Resetting the epigenetic clock: cellular senescence and regenerative strategies in intervertebral disc degeneration.
17-jun-2026
novelty 3
per-area 3
strengthens
Intervening in aging and related diseases with gene therapy techniques.
15-jun-2026
novelty 2
per-area 2
strengthens